- Home
- SANA vs PHAR Comparison
SANA vs PHAR Comparison
Compare SANA & PHAR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SANA
- PHAR
- Stock Information
- Founded
- SANA 2018
- PHAR 1988
- Country
- SANA United States
- PHAR Netherlands
- Employees
- SANA N/A
- PHAR N/A
- Industry
- SANA Medicinal Chemicals and Botanical Products
- PHAR Biotechnology: Pharmaceutical Preparations
- Sector
- SANA Health Care
- PHAR Health Care
- Exchange
- SANA Nasdaq
- PHAR Nasdaq
- Market Cap
- SANA 983.4M
- PHAR 938.6M
- IPO Year
- SANA 2021
- PHAR N/A
- Fundamental
- Price
- SANA $2.84
- PHAR $14.01
- Analyst Decision
- SANA Strong Buy
- PHAR Strong Buy
- Analyst Count
- SANA 5
- PHAR 3
- Target Price
- SANA $8.75
- PHAR $30.00
- AVG Volume (30 Days)
- SANA 6.2M
- PHAR 11.9K
- Earning Date
- SANA 08-11-2025
- PHAR 10-23-2025
- Dividend Yield
- SANA N/A
- PHAR N/A
- EPS Growth
- SANA N/A
- PHAR N/A
- EPS
- SANA N/A
- PHAR N/A
- Revenue
- SANA N/A
- PHAR $339,836,000.00
- Revenue This Year
- SANA N/A
- PHAR $16.63
- Revenue Next Year
- SANA N/A
- PHAR $6.77
- P/E Ratio
- SANA N/A
- PHAR N/A
- Revenue Growth
- SANA N/A
- PHAR 22.44
- 52 Week Low
- SANA $1.26
- PHAR $6.73
- 52 Week High
- SANA $7.30
- PHAR $17.08
- Technical
- Relative Strength Index (RSI)
- SANA 35.84
- PHAR 60.62
- Support Level
- SANA $2.98
- PHAR $13.12
- Resistance Level
- SANA $3.49
- PHAR $15.00
- Average True Range (ATR)
- SANA 0.25
- PHAR 0.58
- MACD
- SANA -0.05
- PHAR 0.16
- Stochastic Oscillator
- SANA 2.09
- PHAR 75.12
About SANA Sana Biotechnology Inc.
Sana Biotechnology Inc is a biotechnology company. The company develops engineered cells as medicines and therapies to treat diseases. It is engaged in developing cell engineering programs for across a broad array of therapeutic areas with unmet treatment needs, including oncology, diabetes, B-cell-mediated autoimmune, and central nervous system (CNS) disorders, among others. Its pipeline of product candidates is comprised of SC291, SC262, SC255, UP421 and others.
About PHAR Pharming Group N.V.
Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.